Management of hepatocellular carcinoma in the time of COVID-19
- PMID: 32330540
- PMCID: PMC7172712
- DOI: 10.1016/j.annonc.2020.04.007
Management of hepatocellular carcinoma in the time of COVID-19
Conflict of interest statement
Disclosure MI: speaking and teaching: Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, Guerbet, EISAI; consultant: BTG-Boston Scientific, Bayer. AS: speaker Bureau: Bayer, Gilead Science, Janssen, BTG, AbbVie, Novartis; Advisory board: Tiziana Life Sciences. GC and GR: no conflicts of interest declared. PL: advisory board/speaker bureau for BMS, Roche, Gilead Sciences, GSK, AbbVie, MSD, Arrowhead, Alnylam, Janssen, Spring Bank, MYR, Eiger. GC, GR: no conflicts of interest declared.
Comment on
-
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.Ann Oncol. 2020 Jul;31(7):894-901. doi: 10.1016/j.annonc.2020.03.296. Epub 2020 Mar 26. Ann Oncol. 2020. PMID: 32224151 Free PMC article.
